This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Joan Stephenson, PhD

JAMA. 1999;281:978.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The first AIDS vaccine trial in Africa has been launched in Uganda, announced the National Institute of Allergy and Infectious Diseases (NIAID), which is sponsoring the phase 1 study.

The HIV vaccine involved in the trial uses three HIV genes inserted into a weakened version of the canarypox virus. This vaccine has already undergone safety testing in about 800 people in the United States and France, with no serious adverse effects reported.

The study, which will last for about a year, will enroll 40 healthy HIV-negative adults, who will be randomly assigned to receive four injections of the vaccine, a canarypox rabies vaccine, or a placebo. Researchers will continue to monitor safety and durability of immune responses to the vaccine for an additional year.

Although the main purpose of the trial is to assess safety, investigators will also attempt to evaluate the vaccine's potential for protecting against . . . [Full Text of this Article]